Innovation in bone healing and tissue repair

Kuros is developing a family of bone healing products to address indications in trauma, and spine. These products are called orthobiologics. Kuros is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion.

Kuros has received market approval for:

  • MagnetOs Granules, a novel synthetic bone graft substitute designed to regenerate bone in various locations in the body. This product has obtained CE Mark approval in the EU and 510k approval in the US.

Kuros is developing the following orthobiologic product candidates:

  • MagnetOs Putty, a moldable formulation of MagnetOs Granules. This product is being prepared for submission seeking EU and US market clearance.

  • KUR-111 is a bone graft substitute designed to be a highly efficacious alternative to autograft. KUR-111 is initially being developed for the treatment of tibial plateau fractures and has met the primary endpoint in a Phase II clinical study.

  • KUR-113 is an orthobiologic designed to support healing of fractures that have a risk of not healing properly. KUR-113 is initially being tested in tibial shaft fractures and has met the primary endpoint in a Phase II clinical study.

  • KUR-113 is also being developed as a bone graft for spinal fusion in patients with degenerative disc disease.

  • KUR-112 is a product candidate for patients with solitary bone cysts.
Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 44 733 47 47   Fax: +41 44 733 47 40   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Management
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    MagnetOs
    Spinal fusion
    KUR-113
    MagnetOs
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Surface Science Technology
  3. Synthetic Cross-Linking Technology
  4. Fibrin-Based
  5. Immune Modulation
  6. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Orthobiologics

Kuros is developing a family of bone healing products to address indications in trauma, and spine. These products are called orthobiologics. Kuros is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion.

Kuros has received market approval for:

  • MagnetOs Granules, a novel synthetic bone graft substitute designed to regenerate bone in various locations in the body. This product has obtained CE Mark approval in the EU and 510k approval in the US.

Kuros is developing the following orthobiologic product candidates:

  • MagnetOs Putty, a moldable formulation of MagnetOs Granules. This product is being prepared for submission seeking EU and US market clearance.

  • KUR-111 is a bone graft substitute designed to be a highly efficacious alternative to autograft. KUR-111 is initially being developed for the treatment of tibial plateau fractures and has met the primary endpoint in a Phase II clinical study.

  • KUR-113 is an orthobiologic designed to support healing of fractures that have a risk of not healing properly. KUR-113 is initially being tested in tibial shaft fractures and has met the primary endpoint in a Phase II clinical study.

  • KUR-113 is also being developed as a bone graft for spinal fusion in patients with degenerative disc disease.

  • KUR-112 is a product candidate for patients with solitary bone cysts.